- Home
- USPH vs NVCR Comparison
USPH vs NVCR Comparison
Compare USPH & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USPH
- NVCR
- Stock Information
- Founded
- USPH 1990
- NVCR 2000
- Country
- USPH United States
- NVCR Switzerland
- Employees
- USPH N/A
- NVCR N/A
- Industry
- USPH Medical/Nursing Services
- NVCR Medical/Dental Instruments
- Sector
- USPH Health Care
- NVCR Health Care
- Exchange
- USPH Nasdaq
- NVCR Nasdaq
- Market Cap
- USPH 1.3B
- NVCR 1.4B
- IPO Year
- USPH 1992
- NVCR 2015
- Fundamental
- Price
- USPH $90.42
- NVCR $14.04
- Analyst Decision
- USPH Strong Buy
- NVCR Buy
- Analyst Count
- USPH 5
- NVCR 7
- Target Price
- USPH $110.20
- NVCR $28.79
- AVG Volume (30 Days)
- USPH 157.8K
- NVCR 1.9M
- Earning Date
- USPH 11-04-2025
- NVCR 10-30-2025
- Dividend Yield
- USPH 2.00%
- NVCR N/A
- EPS Growth
- USPH 116.39
- NVCR N/A
- EPS
- USPH 2.29
- NVCR N/A
- Revenue
- USPH $722,201,000.00
- NVCR $630,160,000.00
- Revenue This Year
- USPH $18.73
- NVCR $6.68
- Revenue Next Year
- USPH $6.13
- NVCR $7.01
- P/E Ratio
- USPH $39.36
- NVCR N/A
- Revenue Growth
- USPH 16.25
- NVCR 14.58
- 52 Week Low
- USPH $62.77
- NVCR $10.87
- 52 Week High
- USPH $101.20
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- USPH 70.17
- NVCR 60.46
- Support Level
- USPH $83.44
- NVCR $12.61
- Resistance Level
- USPH $91.43
- NVCR $14.77
- Average True Range (ATR)
- USPH 3.09
- NVCR 0.55
- MACD
- USPH 0.97
- NVCR 0.19
- Stochastic Oscillator
- USPH 88.38
- NVCR 67.68
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.